Millipore Sigma Vibrant Logo

07-1318 Anti-phospho-JAK2 (Tyr317) Antibody

Detect phospho-JAK2 (Tyr317) using this Anti-phospho-JAK2 (Tyr317) Antibody validated for use in WB.

Anti-phospho-JAK2 (Tyr317) Antibody: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.
Research Category: Signaling Gene Symbol: EC 2.7.10.2, JAK-2, JTK10 , OTTHUMP00000021024, OTTHUMP00000043260 UniProt Number: O60674
View Products on Sigmaaldrich.com
07-1318
100 µL  
Preis wird abgerufen...
Preis nicht abrufbar
Die Mindestmenge muss ein Vielfaches sein von
Maximum Quantity is
Bei Bestätigung Weitere Informationen
Sie haben () gespart
 
—
Bitte erfragen
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      Sonderaktionen

       

      Kontakt zum Kundenservice

      Übersicht

      Replacement Information

      Sonderaktionen

      100% Performance Guaranteed

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWBRbSerumPolyclonal Antibody
      Description
      Catalogue Number07-1318
      DescriptionAnti-phospho-JAK2 (Tyr317) Antibody
      Alternate Names
      • Janus kinase 2
      • Janus kinase 2 (a protein tyrosine kinase)
      • tyrosine-protein kinase JAK2
      Background InformationJAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies.
      References
      Product Information
      FormatSerum
      PresentationRabbit serum with 0.05% sodium azide.
      Quality LevelMQ100
      Applications
      ApplicationDetect phospho-JAK2 (Tyr317) using this Anti-phospho-JAK2 (Tyr317) Antibody validated for use in WB.
      Key Applications
      • Western Blotting
      Biological Information
      ImmunogenKLH-conjugated recombinant protein selected from residues corresponding to Tyr317 of JAK2.
      EpitopeTyr317
      HostRabbit
      SpecificityThis antibody recognizes phosphorylated JAK2.
      Species Reactivity
      • Human
      Species Reactivity NoteProven to react with human.
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • EC 2.7.10.2
      • JAK-2
      • JTK10
      • OTTHUMP00000021024
      • OTTHUMP00000043260
      Modifications
      • Phosphorylation
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION: Plays a role in leptin signaling and control of body weight By similarity. Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.
      CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
      SUBUNIT STRUCTURE: Interacts with SIRPA and SH2B1 By similarity. Interacts with IL23R, SKB1 and STAM2.
      SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane protein By similarity. Note: Wholly intracellular, possibly membrane associated By similarity.
      TISSUE SPECFICITY: Expressed in blood, bone marrow and lymph node.
      DOMAIN: Possesses two phosphotransferase domains. The second one probably contains the catalytic domain By similarity, while the presence of slight differences suggest a different role for domain 1.
      PTM: Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813 By similarity.
      INVOLVEMENT IN DISEASE: Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.
      Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites.
      Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients.
      Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.
      Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
      Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
      SEQUENCE SIMILARITIES: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
      Contains 1 FERM domain.
      Contains 1 protein kinase domain.
      Contains 1 SH2 domain.
      Molecular Weight130 kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blot in JAK2 IP lysate (see below).
      Western Blot Analysis: A 1:500 dilution of this antibody detected phospho-JAK2 (Tyr317) on JAK2 IP lysate.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      07-1318 04053252586903